The Janssen RORgt inhibitor, JNJ-61803534 , is an oral clinical candidate that was well-tolerated in humans up to 200 mg and demonstrated PD. Unfortunately, development was terminated due to findings in a rabbit embryo-fetal study where fetal development was impacted by JNJ-61803534 treatment. The JNJ team shares a lot of useful human data in [...]
< 1 minute read
Sep. 18, 2021
JNJ-61803534: An Oral RORγt Inverse Agonist
JNJ-61803534
oral ROR_t inverse agonist Ph. I in HV up to 200 mg w/ PD, discontinued from HTS + opt. Scientific Reports, May 26, 2021 Janssen R&D, La Jolla, CA